文献速递淋巴瘤

免疫治疗时代弥漫大B细胞淋巴瘤一致性骨髓累及代表独特的临床与生物学实体

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
PubMed 文献 · Leukemia · 2017-07-12

该研究评估了712例接受一线含利妥昔单抗治疗的初治弥漫大B细胞淋巴瘤(DLBCL)患者,其中263例骨髓阳性、449例骨髓阴性。一致性骨髓累及独立于国际预后指数(IPI)和细胞起源分类,对总生存和无进展生存产生不良影响;而不一致性骨髓累及患者的总生存与I-II期DLBCL相似。

要点

  • 一致性骨髓累及是DLBCL的独立不良预后因素,不受IPI和细胞起源分类影响。
  • 不一致性骨髓累及患者的总生存与I-II期DLBCL相似。
  • 包含一致性骨髓累及、年龄>60岁和体能状态>1的骨髓调整IPI可改善骨髓阳性DLBCL的风险分层。

核心结论

  • 骨髓阳性DLBCL存在临床和生物学异质性,一致性骨髓累及代表具有不良基因特征、高危临床病理特征和不良预后的独特亚群。

研究设计与样本

  • 研究纳入712例接受一线含利妥昔单抗治疗的初治DLBCL患者,其中263例骨髓阳性、449例骨髓阴性。

主要发现

  • 与骨髓阴性相比,一致性骨髓累及对总生存和无进展生存产生不良影响,独立于IPI和细胞起源分类。
  • 一旦骨髓一致性累及,不良预后与骨髓累及程度无关。
  • 不一致性骨髓累及患者的总生存与I-II期DLBCL相似。
  • 使用一致性骨髓累及、年龄>60岁和体能状态>1三个参数的骨髓调整IPI改善了骨髓阳性DLBCL的风险分层。
  • 强化免疫化疗似乎为一致性骨髓累及患者带来生存获益,利妥昔单抗维持治疗似乎为不一致性骨髓累及组带来生存获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In diffuse large B-cell lymphoma (DLBCL), the clinical and biological significance of concordant and discordant bone marrow (BM) involvement have not been well investigated. We evaluated 712 de novo DLBCL patients with front-line rituximab-containing treatment, including 263 patients with positive and 449 with negative BM status. Compared with negative BM disease, concordant BM adversely impacted overall and progression-free survival, independent of the International Prognostic Index (IPI) and cell-of-origin classification. Once BM is concordantly involved, poor prognosis was not associated with the extent of BM involvement. Conversely, patients with discordant BM showed favorable overall survival similar to stage I-II DLBCL. A BM-adjusted IPI, using three parameters: concordant BM involvement, age >60 years, and performance status >1, improves the risk stratification for DLBCL with positive BM. Intensive immunochemotherapy seemingly rendered survival benefit for patients with concordant BM, as did rituximab maintenance for the discordant BM group. Frequently revealing adverse clinical and molecular characteristics, patients with concordant BM demonstrated gene expression signatures relevant to tumor cell proliferation, migration and immune escape. In conclusion, clinical and biological heterogeneity is seen in DLBCL with positive BM but concordant BM involvement represents a distinct subset with unfavorable gene signatures, high-risk clinicopathologic features and poor prognosis.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yao Z, Deng L, Xu-Monette ZY, et al. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia. 2017. PMID: 28745330. doi:10.1038/leu.2017.222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。